Viewing Study NCT05218902

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 3:55 AM

Ignite Modification Date: 2026-01-12 @ 11:37 AM

Study NCT ID: NCT05218902

Status: COMPLETED

Last Update Posted: 2023-05-31

First Post: 2022-01-20

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Sponsor: Bristol-Myers Squibb

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module